Arca
Skip to content

Squamous cell carcinoma

Drug research and approvals for squamous cell carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 858 studies of squamous cell carcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 77 drug trials for it since 2013, FDA has 9 approved and 8 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 858
  • Trials authorized in Canada: 77
  • FDA orphan approvals: 9
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 858 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 77; search them all in Canada trials
Oct 22, 2026A phase 3, randomized, open-label, multicenter trial of amivantamab as sequential therapy following definitive, platinum-based, concurrent chemoradiotherapy,…RYBREVANT (AMIVANTAMAB0Johnson & JohnsonPending
Oct 2, 2026A phase 2/3 multicenter, randomized, open-label study of asp-1929 photoimmunotherapy in combination with pembrolizumab versus standard of care in the…ASP-1929 (CETUXIMAB-IR700)RAKUTEN MEDICAL, INC.Pending
Jun 26, 2026A phase 1/2, open-label trial to evaluate safety, immunogenicity, and anti-tumor activity of vb10.16 in combination with pembrolizumab in patients with…VB10.16 (ABIPAPOGENE SUVAPLASMID) / PEMBROLIZUMABNYKODE THERAPEUTICS ASAPending
Apr 23, 2026A phase 1 first-in-human, open-label study evaluating the safety, pharmacokinetics, and efficacy of abbv-711 as a monotherapy or in combination with…ABBV-711 / BUDIGALIMAB (ABBV-181)AbbVieOngoing
Dec 19, 2025Capecitabine prior to tumor resection in entoncology (capture)CAPECITABINERESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTREPending
Dec 10, 2025Gsk5764227 (anti-b7h3 antibody drug conjugate) monotherapy or in combination with dostarlimab in recurrent/metastatic (r/m) head and neck squamous cell…GSK5764227 / DOSTARLIMABUNIVERSITY HEALTH NETWORKOngoing
Aug 7, 2025A randomized, phase 3, open-label study to evaluate pf-08046054 / sgn pdl1v in combination with pembrolizumab vs pembrolizumab monotherapy in adult…PF-08046054 (SGN-PDL1V) / KEYTRUDAPfizerClosed
Apr 3, 2025Randomized phase III trial of neoadjuvant immunotherapy with response adapted treatment versus standard-of-care treatment for resectable stage iii/iv cutaneous…LIBTAYO [CEMIPLIMAB (REGN2810)]CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITYOngoing
Jun 5, 2024A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of…MCLA-158 (PETOSEMTAMAB) / KEYTRUDAMERUS N.V.Ongoing
Apr 19, 2024A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator¿s choice monotherapy…MCLA-158 (PETOSEMTAMAB) / ERBITUX (CETUXIMAB) / METHOTREXATE INJECTION USP…GenmabOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 17
May 15, 2025Zynyzin combination with carboplatin and paclitaxel, for the first-line treatment of adult patients with inoperable locally recurrent or…Incyte CorporationApproved
Mar 3, 2025Tevimbrain combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal…BeOne Medicines USA, Inc.Approved
Mar 13, 2024Tevimbraas a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior…BeOne Medicines USA, Inc.Approved
May 27, 2022OpdivoIn combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous…Bristol-Myers Squibb CompanyApproved
May 27, 2022OpdivoIn combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with…Bristol-Myers Squibb CompanyApproved
Jun 10, 2020OpdivoOpdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell…Bristol-Myers Squibb CompanyApproved
Jul 30, 2019KeytrudaKEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus…MSD International Business GmbHApproved
Jun 13, 2014LYMPHOSEEKGuiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of…Cardinal Health 414, LLCApproved
Mar 1, 2006ErbituxFor use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and…ImClone Systems IncorporatedApproved
Mar 24, 2025an anti-CD228 monoclonal antibody conjugated with MMAE…treatment of metastatic (stage IV) lung squamous cell carcinomaShandong Boan Biotechnology Co., Ltd.Designated
Jan 7, 2021zinflavonoidsTreatment of anatomical sites of squamous cell carcinoma of oral cavity and oropharynx accessible for local and topical administrationAveta Biomics, Inc.Designated
Sep 4, 2014Adenovirus serotype-5 (Ad5) vector that contains a modified…Treatment of human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC)Etubics CorporationDesignated
Jan 12, 2009HPV-16 cancer therapeutic trojan peptide vaccineTreatment of HPV-16 expressing head and neck squamous cell carcinoma.Gliknik, Inc.Designated
May 4, 2007leukocyte interleukinNeoadjuvant therapy in patients with squamous cell carcinoma of the head and neckCEL-SCI CorporationDesignated
Jul 7, 2005human leukocyte-derived cytokine mixtureNeoadjuvant therapy in patients with squamous cell carcinoma of the head and neckIRX Therapeutics, Inc.Designated

Medicines Authorised in the EU

Newest first
Apr 19, 2024Zynyzretifanlimab · orphanIncyte Biosciences Distribution B.V.EMA ↗
Sep 15, 2023TevimbratislelizumabBeone Medicines Ireland LimitedEMA ↗
Jun 28, 2019LibtayocemiplimabRegeneron Ireland Designated Activity Company (DAC)EMA ↗
Oct 24, 2001FoscantemoporfinBiolitec Pharma LtdEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.